{"url_path":"/sec/nmtc/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","accession_number":"0001213900-26-054749","cik":"0001500198","ticker":"NMTC","issuer_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","primary_entity_key":"0001500198","primary_entity_name":"NEUROONE MEDICAL TECHNOLOGIES Corp"},"word_count":73,"has_tables":true,"body_markdown":"**Item 2. Unregistered\nSales of Equity Securities and Use of Proceeds**\n\n \n\nOn March 1, 2026, the\nCompany entered into a securities purchase agreement with a newly appointed officer of the Company, David Wambeke, to issue and sell\n166,666 shares of the Company’s common stock at a price per share equal to $4.022. The foregoing issuance of securities was made\npursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act."}